Trial
NCT03381833
A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
La Jolla Pharmaceutical Company
Collaborators
—
Condition
Beta-Thalassemia
Intervention
LJPC-401
Why stopped
Terminated early for lack of efficacy as determined by interim endpoint analyses
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-07-29